Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates Medical Dialogues Bureau30 Oct 2019 9:30 AM ISTPfizer said it expects to earn between $2.94 per share and $3.00 per share, up from a prior estimate of $2.76 to $2.86. Analysts on average were...